Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%
Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

At a Glance

Live Snapshot
Market Cap$357.74M
EPS0.1900
P/E Ratio55.84
Earnings Date

dmaa

Net Debt Issuance

Last Annual Value

-900.00K

3-Year CAGR

-41%

5-Year CAGR

-23%

10-Year CAGR

-11%

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors Analysis of Net Debt Issuance

DMAA · NASDAQ
CompanyNet Debt Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
-900.00K
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
-99.20K
N/AN/AN/A
-239.49K
N/AN/AN/A
-176.57K
N/AN/AN/A
250.00K
N/AN/AN/A
-221.56K
N/AN/AN/A
-221.56K
N/AN/AN/A
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope

DMAA · NASDAQ

Our analysis suggests that DMAA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.61, this represents a potential HIDDEN relative to our calculated worth for Drugs Made In America Acquisition Corp. Ordinary Shares.

Intrinsic Value
Current Price: $10.61